Skip to content
Biodatica
Start free

NGM Biopharmaceuticals, Inc

Glendale, Arizona

OncologyPhase II
Compare Sign in to watch

What changed

Phase II trial registered: An Evaluation of NGM120 in a Randomized, Double-blind, Placebo-controlled Study in Participants With Colorectal Cancer Who Have Cancer Cachexia.

3mo agoTrial registeredApr 1, 2026Source filing (opens the source filing in a new tab)

Momentum

72no change

Momentum 72 out of 100, unchanged since the last recompute.

Accelerating: several high-weight events landed recently.

Runway (estimate)

—unknown

No disclosed raise on file, so there is nothing to model from.

Stage

Phase II

The furthest-along thing in the public record. Not a projection.

Runway is an estimate: the last disclosed raise (SEC Form D) minus a modeled burn rate for the company’s stage and therapeutic area. It is not a disclosure, and companies routinely raise non-dilutive money we can’t see. How this is calculated.

Peer position

1,008 pre-ticker oncology companies at Phase II

Peer ranking — where this company sits among its stage-and-area peers by momentum, and how its runway compares to the peer median — is part of the Analyst tier.

Compare seats

A ranking of the same momentum figure the feed publishes, computed live against public-filing peers. It is a relative position, not a recommendation, and it is identical for every viewer.

Grant to raise

Every record Biodatica has resolved onto this company, newest first, each linked to the filing it came from. Where a source publishes no stable deep link for a record, the identifier is shown so you can look it up yourself.

  1. Trial

    PHASE2 registered

    Jun 25, 2025

    Colorectal Cancer, CRC (Colorectal Cancer), Cancer Cachexia · RECRUITING · sponsor: NGM Biopharmaceuticals, Inc · An Evaluation of NGM120 in a Randomized, Double-blind, Placebo-controlled Study in Participants With Colorectal Cancer Who Have Cancer Cachexia.

    ClinicalTrials.gov · NCT07033026 (opens the source filing in a new tab)

  2. Trial

    PHASE2 registered

    Mar 23, 2020

    Compensated Cirrhosis, Nonalcoholic Steatohepatitis · COMPLETED · sponsor: NGM Biopharmaceuticals, Inc · Study of Aldafermin (NGM282) in Subjects With Compensated Cirrhosis (ALPINE 4)

    ClinicalTrials.gov · NCT04210245 (opens the source filing in a new tab)

  3. Trial

    PHASE2 registered

    May 16, 2019

    NASH - Nonalcoholic Steatohepatitis · COMPLETED · sponsor: NGM Biopharmaceuticals, Inc · Evaluation of Efficacy, Safety and Tolerability of Aldafermin in a Phase 2b, Randomized, Double-blind, Placebo-controlled, Multi-center Study In Subjects With Nonalcoholic Steatohepatitis and Stage 2/3 Fibrosis (ALPINE 2/3)

    ClinicalTrials.gov · NCT03912532 (opens the source filing in a new tab)

Biodatica publishes impersonal research shown identically to every subscriber. This dossier is informational only, it is not investment advice, and the momentum and runway figures are estimates derived from public filings. The underlying records are U.S. government works. Disclosures · Data sources